Skip to main content
Premium Trial:

Request an Annual Quote

GenapSys Raises up to $75M in Debt Funding, Signs on More Than 25 Distributors

NEW YORK – Sequencing technology company GenapSys said on Thursday that it has raised up to $75 million in debt funding from Oxford Financing and has signed deals with more than 25 distributors worldwide.

The debt funding will go toward the company's commercialization activities as it is launching its sequencing platform globally.

Specifically, GenapSys said it is releasing it sequencer in the Asia-Pacific (APAC) region, including in China, Korea, Singapore, and Japan. Among the firm's distributors are Research Instruments of Singapore, Biomedical Systems of Korea, and Gene Company of Hong Kong.

GenapSys, based in Redwood City, California, also said it is seeking to partner with local health agencies and researchers to use its sequencing platform to study the new coronavirus that is currently spreading in China and beyond.

Last November, the company launched its lunchbox-sized electronic sequencer, which uses microfluidic CMOS chips and has a list price of $10,000.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.